Histidyl-proline diketopiperazine (His-Pro DKP) cells in the pancreas of human fetuses aged between 12 and 19 wk were localized by the indirect antibody-enzyme method on semithin sections. To study their fine structure, two techniques were used: a superimposition technique consisting of comparison of the same cells in semithin and electron microscopic preparations, and an immunocytochemical technique on ultrathin sections using the unlabeled antibody peroxidase-antiperoxidase method. Our results show that (a) the same cells are positive for both His-Pro DKP and glucagon/glicentin, (b) His-Pro DKP immunoreactive cells possess extremely electron-opaque secretory granules, implying that these cells correspond to the A cells, and (c) HisPro DKP immunoreactivity is found over the secretory granules. We hypothesize that the two peptides His-Pro DKP and thyrotropin-releasing hormone (TRH) have independent origins, since TRH is found in the B cells.
Introduction
Histidyl-proline diketopiperazine (His-Pro DKP),' a cyclic dipeptide initially described in both the hypothalamus and cerebral tissues (1) (2) (3) (4) , has been detected in various sites outside the central nervous system (5, 6) , including the gastrointestinal tract and, more specifically, the endocrine pancreas (7) . There has been some controversy over the relationship of endogenous His-Pro DKP to thyrotropin-releasing hormone (TRH). Although it was initially proposed that His-Pro DKP was a metabolite of TRH (8-1 1) , recent studies suggest that most of His-Pro DKP is independent of the tripeptide amide (12, 13) . Pancreatic His-Pro DKP appears to be chromatographically and immunologically identical to the synthetic dipeptide (7) , but its role is unknown. The cyclic dipeptide is not localized in the insulin-containing cells, since His-Pro DKP content, unlike TRH (14) , remains unaltered after the selective destruction of B cells by streptozotocin (7) .
In the present experiment we examined the localization of His-Pro DKP immunoreactivity in the human fetal pancreas by light and electron microscopic immunocytochemistry. This model offers a number of potential advantages in clarifying the origin of His-Pro DKP. While pancreatic TRH is easily detected in the fetal and early neonatal period in the rat, the levels gradually decline during the neonatal period and are basely detectable in the adult (15) (16) (17) (18) . In contrast, the content of His-Pro DKP in the pancreas peaks in the adult rat (12) . In light ofpreliminary studies demonstrating the simultaneous occurrence of both insulin and TRH immunoreactivity in the same islet cells of the human fetal pancreas (19), we have used this system to further clarify the cellular location of His-Pro DKP and its relationship to TRH.
Methods
Tissue collection. Eight pancreatic glands were collected from human fetuses (six females and two males) delivered after legal abortions. The crown-rump length of the fetuses ranged from 6 to 14 cm (i.e., 12-19 wk of gestation) (20) . Our study was carried out according to guidelines established by the National Ethical Committee of France. Tissue preparation. To preserve His-Pro DKP immunoreactivity, a combination ofp-formaldehyde (4% wt/vol) and low glutaraldehyde (0.5% vol/vol) was used in the primary fixation step, followed by postfixation with 1% osmium tetroxide as reported for TRH (19) . After embedding in araldite, semithin l-Am and ultrathin 90-nm sections were cut. Semithin sections were deresinated for 10-30 min with sodium ethoxide (21 (27) (28) (29) (30) (31) (32) .
Immunocytochemistry on semithin sections: light and electron microscopy. The immunocytochemical procedure performed on serial l-,gm sections using the goat anti-rabbit immunoglobulin G conjugated to peroxidase (33) was applied as described previously (30) . Semithin sections were examined in a Zeiss light microscope. For electron microscopy, immunoreactive cells were photographed and the corresponding ultrathin sections of the same cells, contrasted with lead citrate, were examined in an Elmiskop 101 electron microscope. The mean values (in nanometers) of granule profile diameter were characterized with the aid of the 95% confidence limits (mean± 1.96 [SD/4Vi]).
Immunocytochemistry on ultrathin sections. The unlabeled antibody peroxidase-antiperoxidase method (34) was applied as described previously (22) . The grids were contrasted with lead citrate before observation.
Primary antisera specificity controls. To test for specificity, antiserum to His-Pro DKP was absorbed with the corresponding antigen (Peninsula Laboratories, Inc.) at concentrations of 10-1,000 nmol/ml undiluted antiserum for 1 h at 37°C. Absorbed antiserum or nonimmune serum were used instead offreshly diluted primary antiserum on control sections. All staining was abolished by absorption of primary antiserum at 250 nmol. Absorption of the anti-His-Pro DKP with heterologous hormones (pancreatic and brain peptides) or hormone fragments (also see reference 19) gave no change in the reaction. The immunoreaction due to anti-COOH-terminal-specific glucagon, anti-glicentin, anti-insulin, anti-somatostatin, or anti-PP was quenched by the corresponding antigen (also see reference 19) . (Fig. 2 A) , and later (16 wk) inside the recognizable islets of Langerhans (Fig. 2 C) . His-Pro DKP immunoreactivity was entirely confined to the peripheral parts of the typical islets (Fig. 2 C) . It was present throughout the pancreatic gland, but its distribution was heterogeneous. Immunoreactive cells were numerous in the superior part of the head, in the body and in the tail, but were only very scarce in the lower posterior part of the head. The exocrine tissue of the fetal pancreas was unstained. Also, no nerve cells or fibers within the pancreas contained HisPro DKP immunoreactivity.
Interrelationship of cells immunoreactive to His-Pro DKP and other hormone antisera. Consecutive semithin sections of 12-19-wk-old fetuses were stained alternately with His-Pro DKP and COOH-terminal-specific glucagon antisera. As shown in Fig. 2 , the same cells in the islet cell clusters (12 wk) or in the typical islets (16-19 wk) revealed the simultaneous occurrence of both His-Pro DKP and COOH-terminal glucagon immunoreactivity. Similar results were obtained after substitution of glicentin antiserum (that specifically recognizes the glucagon precursor, also see reference 35) in place of the COOH-terminalspecific glucagon antiserum. In contrast, the His-Pro DKP immunoreactive cells were distinct from insulin-and somatostatincontaining cells in the superior part of the head, in the body, and in the tail. No His-Pro DKP immunoreactivity could be detected in the numerous cells containing pancreatic polypeptide of the lower posterior part of the head.
Ultrastructural characterization of His-Pro DKP immunoreactive cells. A superimposition technique, using semithin sections for immunocytochemistry and consecutive ultrathin sections for ultrastructural characterization, were then adopted. His-Pro DKP immunoreactive cells observed in the consecutive ultrathin sections all shared a number of characteristics. They possessed a population of extremely electron-opaque secretory granules with two components: an eccentric spherical core and a granular mantle, the latter usually less dense (Fig. 3) . The granule profile diameter varied considerably within a given cell and between different cells, and ranged from 250 to 600 nm; their size distribution is shown in Fig. 5 . The mean value (nanometers±confidence limits 95%) of the profile diameter was 416±4.14. His-Pro DKP immunoreactive cells corresponded to the A cells. As shown in Fig. 3 , there was another cell type with granules -300-600 nm in diameter, but whose granules dis- played a paracrystalline core and a broad halo. This cell type was referred to as B cells. As previously reported (19) , the mean profile diameter (nanometers±confidence limits 95%) was 442±5.04. The D cells, in contrast, contained large granules (-300-950 nm in diameter) with clear contents surrounded by a broken limiting membrane (Fig. 3) . The mean profile diameter (nanometers±confidence limits 95%) was 716±7.78. The B and D cells were not stained on semithin sections (Fig. 3) .
Ultrastructural localization of His-Pro DKP. Immunocytochemical staining with His-Pro DKP antiserum gave a precise localization of the cyclic dipeptide in the cytoplasmic granules. The reaction product (electron-dense precipitates at least 30 nm in diameter) was deposited on electron-opaque secretory granules, leading to the conclusion that these cells corresponded to the A cells (Fig. 4) . The reaction product usually stained the whole surface of the secretory granules (Fig. 4) , as reported for glucagon (19) .
Discussion
His-Pro DKP has been measured biochemically in the pancreas and, more specifically, in the islets of Langerhans, however its precise localization was unknown except that the cyclic dipeptide is not concentrated in streptozotocin-sensitive cells (7) . As reported herein, its cellular location in the A cells revealed by immunocytochemistry may be taken as indicative of a potential relationship to other hormones and of functional relations between His-Pro DKP and the endocrine pancreas.
In the present paper, we have reported the presence of a strong His-Pro DKP immunostaining in the human fetal pancreas. Its cellular location has been assigned to an endocrinetype cell, predominantly confined to the periphery of islets. A general problem with immunocytochemical methods is the specificity of the technique, especially the possible existence of cross-reacting antibodies. This is a particularly important issue when using antisera raised to small peptides, such as the cyclic dipeptide His-Pro DKP. The radioimmunoassay and absorption tests suggest that each primary anjiserum is not only specific to one peptide family but that, within its family, it is also specific to the peptide that has produced the antiserum.
Three techniques were used to characterize its localization: (a) consecutive semithin sections alternately stained with HisPro DKP and other antisera; (b) superimposition of immunocytochemical and electron microscopic observations on the same cells; and (c) immunocytochemical staining on ultrathin sections. glucagon antisera, respectively (39 35) immunoreactivity (30, 40 (8-1 1). Because the putative parent tripeptide TRH has been assigned to the pancreatic B cells in neonatal (46) , streptozotocin-treated newborn (14) , and hypothyroid (32) rat, and in the human fetus (19), we further hypothesize (12, 13) that the two peptides His-Pro DKP and TRH have independent origins. Recently the presence of HisPro DKP immunoreactivity in the mammalian cerebrospinal fluid has been reported (47) . This study also suggests that at least a certain portion of His-Pro DKP may be derived from sources independent ofTRH. There is, however, one report ofpancreatic TRH in some of the cells reactive to glucagon antiserum in developing rat pancreas (46) . Unfortunately, absorption tests with the His-Pro DKP antigen were not carried out in that study. One report has also indicated a possible role in the modulation of islet hormonal responses to nutrients, and in the catecholaminergic control of islet secretory events (7) . If the co-localization of His-Pro DKP and glucagon is confirmed by other techniques, His-Pro DKP may play a role in glucagon physiology. However, it is not inconceivable that other roles may exist, specifically related to the regulation ofdifferentiation and/or growth of fetal cells.
